StocksMedium•9 November 2026•
1 min read
Oruka Therapeutics Reports Q3 2026 Results and Positive ORKA-001 Clinical Data
Key Facts
1EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group.
Oruka Therapeutics reported its third-quarter 2026 financial results alongside clinical data from its EVERLAST-B trial for ORKA-001. GlobeNewswire reported that Week 16 results showed 61% of patients achieved a PASI 100 response and 86% achieved PASI 90 in the high-dose group. The company posted a net loss of $50.0 million for the third quarter of 2026, compared to a net loss of $30.3 million in the same period of 2025.
Research and development expenses reached $53.7 million for the third quarter, while general and administrative expenses stood at $8.4 million. Regarding market performance, ORKA closed at $102.86 on November 6, 2026, having traded between a day high of $103.78 and a day low of $96.05.